News & Blogs

The Inflation Reduction Act’s broken promise is still costing patients

When President Biden signed the Inflation Reduction Act into law, his administration promised it would make prescription drugs more affordable and accessible for seniors. Yet the results tell a different story. A recent analysis found that nearly one in four initial attempts by patients to fill a prescription for one of the first drugs selected for Medicare’s drug price negotiation program was rejected. Patients relying on immunology and oncology treatments felt this even more intensely,…

Learn More

Use Trade Policy to Push Wealthy Nations to Pay More for Meds

President Trump just announced another round of agreements with pharmaceutical companies under his “most-favored-nation” drug pricing initiative. The nine new deals bring the total number of participating manufacturers to 26, covering nearly 90% of the branded-drug market. The campaign targets a real problem. Many wealthy countries use price controls to pay far less for new medicines than Americans do.

Learn More

How to Win 2026 Part 5: A Healthier America

American families are paying nearly the price of a new car every year just for job-based family health insurance. Then come the deductibles, copayments, prescription drugs, and medical bills that too often seem impossible to understand. Healthcare is nearly one-fifth of the American economy. It affects affordability, wages, the federal budget, and ultimately whether Americans live healthier and longer lives. That makes healthcare one of the most important issues in the 2026 election. In the…

Learn More

It’s Time To Stop Wealthy Nations Freeloading on US Medicines

For over a year, German officials have obstructed one of the Trump administration’s most important reform initiatives. And the president’s patience just ran out. The White House has repeatedly asked allied countries to roll back their price controls on prescription drugs. If those nations started paying market prices for medicines invented and manufactured in the United States, it would relieve the pressure on American patients, employers, and taxpayers—who are currently forced to fund a disproportionate…

Learn More

Biden-Era Law That Created Medicare Drug Price Controls Could Hike Up Prices, Analysts Warn

Medicare’s drug price controls could restrict Americans’ ability to access care and potentially drive up costs in the long term, according to analysts. The Inflation Reduction Act (IRA), signed into law by then-President Joe Biden in August 2022, authorized the U.S. federal government to negotiate prices for certain high-cost prescription drugs covered by Medicare through the Medicare Drug Price Negotiation Program. While congressional Democrats previously claimed the IRA would help bring down healthcare prices, analysts warned the Daily Caller News Foundation that such price controls might limit…

Learn More

States Should Not Wait Until 2028 to Open PBMs’ Books

Prescription drug prices do not become opaque by accident. They become opaque because the middlemen who manage drug benefits are allowed to hide many of their revenue streams from the employers, insurers, pharmacies, and patients who ultimately pay the bill. Congress has already recognized the problem. Federal pharmacy benefit manager (PBM) reporting requirements are scheduled to reshape what PBMs must disclose, but many of the most important provisions will not take effect until 2028. That delay creates…

Learn More

Competition, Not Price Controls, Cut Drug Costs

Here’s one sign the affordability crisis isn’t what it used to be. You’ve probably seen the headlines. Big win here for Trump, but also for free market competition. The Trump Administration has aggressively promoted direct-to-consumer sales and included PBM reforms in the Big Beautiful Bill. Team Trump has attracted a half trillion dollars in new biopharmaceutical investment to the US. Intense market competition is driving down the price of medicines, such as popular weight loss…

Learn More